Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer Article (Faculty180)

cited authors

  • Liu, Chengfei; Lou, Wei; Zhu, Yezi; Nadiminty, Nagalakshmi; Schwartz, Chad T; Evans, Christo P; Gao, Allen C


  • Enzalutamide, a second-generation antiandrogen, was recently approved for the treatment of castration-resistant prostate cancer (CRPC) in patients who no longer respond to docetaxel. Despite these advances that provide temporary respite, resistance to enzalutamide occurs frequently. Androgen receptor (AR) splice variants such as AR-V7 have recently been shown to drive castration-resistant growth and resistance to enzalutamide. This study was designed to identify inhibitors of AR variants and test its ability to overcome resistance to enzalutamide.

publication date

  • 2014

start page

  • 3198

end page

  • 3210


  • 20